The US Senate is reportedly considering a new bill introduced that would effectively ban so-called “pay-for-delay” deals between pharmaceutical companies. The legislation, with a bipartisan introduction given on Tuesday, would aim to maintain a healthy competitive market as pharmaceutical giants pay their generic counterparts to keep those less expensive generics off the shelves. Name brand manufacturers do-so as a way to resolve patent disputes, which generics potentially infringe upon. The bill is sponsored by Amy Klobuchar (D-MN) and Chuck Grassley (R-IA); Grassley was recently appointed as the new chair of the Senate Judiciary Committee’s antitrust panel. Similar legislation has failed to pass through Congress in the past due to fights from the pharmaceutical giants the bills would affect. The issue has been on the radar of competition authorities in both the US and Europe.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI